The TriHealth Hatton Research Institute's Oncology research team, and researchers at TriHealth’s Cancer Institute and Mary Jo Cropper Family Center for Breast Care conduct important clinical trials targeting improvements in the prevention and treatment of specific kinds of cancer. Composed of a team of research nurses and clinical research assistants, the TriHealth Hatton Research Institute's Oncology research team has many decades of experience in oncology research.
Clinical trials supported by our Oncology research team include cooperative group trials sponsored by the National Cancer Institute, studies through the Catholic Health Initiative, and Pharmaceutical Trials.
Selected trials:
- Breast
- Gastrointestinal
- Genitourinary
- Gynecology
- Hematology
- Lung Cancer
- Melanoma/Skin
- Molecular Profiling
- Sarcoma
- Other
What is a Clinical Trial?
A clinical trial (also called “clinical research,” “research study,” and “protocol”) is a research study that evaluates a new test, drug or treatment in people to make sure it is safe and effective. Carefully conducted clinical trials are vital to discovering new, better, safer treatments for people, and improve health and quality of life.
Clinical trials are important today for many reasons, including:
- Contributing to improved scientific knowledge about cancer: how to detect it, and how to treat it, and even how to prevent it
- Possibly benefiting individual patients by providing newer and better treatments, and possibly, a cure
More Information
For additional basic information about clinical trials:
- Introduction to Cancer Research
- National Cancer Institute’s brochure: “Taking Part in Cancer Treatment Research Studies”
- National Cancer Institute website
- National Institutes of Health website
- National Comprehensive Cancer Network website
- National Cancer Institute video about volunteering for a clinical trial
- The American Cancer Society
Oncology: Breast |
|
A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL Study). Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
D3614C00001: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC). Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemo-therapy vs. Observation in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
FLEX: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed By Weekly Paclitaxel With Or Without Carboplatin For Node-Positive Or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NSABP B51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy. Learn more. Principal Investigator and Contact information:
Study Coordinator and Contact information:
|
|
S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
SMX 18-001: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
WF 97116: A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment. Learn more. Principal Investigator and Contact information:
Study Coordinator and Contact information:
|
Oncology: Gastrointestinal |
|
A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
EA2187: A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma. Learn More. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
Oncology: Genitourinary |
|
EA8143: A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC). Learn more. Principal Investigator and Contact information:
Study Coordinator and Contact information: |
|
S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nabpaclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Learn More. Principal Investigator and Contact information: Study Coordinator and Contact information: |
Oncology: Gynecology |
|
GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG GY005: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS). Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
NRG CC004: Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer Learn more . Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
LCCC 1326: Metformin with the Levonorgestrel-Releasing Intrauterine Device for the treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
OPTEC: Ohio Prevention and Treatment of Endometrial Cancer (OPTEC) Initiative: Universal Screening for DNA Mismatch Repair Deficiency and Personalized Cancer Treatment. Learn More. Principal Investigator and Contact information: Study Coordinator and Contact information: |
Oncology: Hematology |
|
C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6). Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
TAK-079-1002: An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy. Learn More. Principal Investigator and Contact information: Study Coordinator and Contact information: |
Oncology: Lung Cancer |
|
A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). An ALCHEMIST Treatment Trial. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
| CA209-77T: A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer. Learn More.
Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations. An ALCHEMIST Treatment Trial. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study). Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
S1800A: A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) Learn More. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
S1900A: Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Learn More. Principal Investigator and Contact information: Study Coordinator and Contact information: |
Oncology: Melanoma/Skin |
|
20130193: A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
Oncology: Molecular Profiling |
|
EAY131: Molecular Analysis for Therapy Choice (MATCH). Principal Investigator and Contact information: Study Coordinator and Contact information: Diann Fischesser, RN Angela Hein, RN |
|
EAY131-Z1L: MATCH Treatment sub protocol Z1L:BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors. Principal Investigator and Contact information: Study Coordinator and Contact information: |
Oncology: Sarcoma |
Oncology: Other |
|
BXQ-350.01: Tumor Tissue Sampling for the Purpose of Investigating Saposin C (Sap C) Principal Investigator and Contact information: Study Coordinator and Contact information: |
|
S1714: A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients. Learn more. Principal Investigator and Contact information: Study Coordinator and Contact information: |